Episteme Prognostics sells $5.1M in ongoing $6.02M offering for pancreatic cancer test
Episteme Prognostics has sold $5.09M of a $6.02M equity offering, while its PancEpistemeDx test still lacks prospective clinical proof.
By RuntimeWire Staff · Published
Primary source: SEC
Why it matters
Episteme's round backs a founder translating years of pancreatic cancer research into a treatment-selection test. The value will depend on prospective clinical validation, not another retrospective association.
Surajit Dhara has raised fresh capital for Episteme Prognostics, the Brooklyn precision-medicine developer built around his research into pancreatic cancer and chromatin accessibility. Episteme Prognostics has sold $5,091,997 in an ongoing $6,017,000 equity offering, according to a Form D filed September 4th.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.